Prolia (denosumab)

This case underscores the value of liquid biopsy detected mutations in guiding targeted therapy. Clinical, biochemical, and radiological findings support the potential use of selective RET tyrosine kinase inhibitors for this rare mutation. Serum calcitonin serves as a reliable quantitative biomarker of therapeutic efficacy.

P4, N=102, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

Serial monitoring of TRACP-5b may provide supplementary information for detecting BM progression in patients with NSCLC treated with osimertinib.

Moreover, DNB/BMP-2 significantly improved torsional stiffness and maximum compressive force versus either treatment alone (all P < 0.05). The findings demonstrate that systemic DNB combined with local BMP-2 rapidly promotes femoral metaphyseal bone regeneration in osteoporotic rats.

Pharmacological inhibition of CARM1 (TP-064) effectively suppressed osteoclastogenesis and bone metastasis in denosumab-resistant models. These findings revealed a targetable resistance mechanism and provided a clinically actionable strategy to overcome microenvironment-driven metastasis through dual targeting of tumor and bone niches.

This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.

P4, N=54, Completed, Tuen Mun Hospital | Recruiting --> Completed

Giant cell tumor of bone (GCTB) is an intermediate bone neoplasm defined by recurrent H3F3A mutations and limited systemic treatment options beyond denosumab...Functionally, 3D culture generally reduced sensitivity to many agents while preserving compound-dependent vulnerabilities. These results establish culture dimensionality as a key determinant of therapeutic susceptibility in GCTB PDCs and support incorporating proteome-informed 3D models into translational pipelines to prioritize clinically relevant drug candidates and biomarkers.

She received first-line endocrine therapy (letrozole+ribociclib+goserelin) combined with denosumab. Breast cancer gastric metastasis diagnosis relies on medical history, gastroscopy, and immunohistochemistry (GATA3+, CK7+, CK20-). The combination regimen yielded favorable efficacy, providing clinical reference for similar rare cases.

P4, N=45, Completed, University of Alabama at Birmingham | Active, not recruiting --> Completed

This case is discussed within the context of a comprehensive narrative review highlighting the distinct biological behavior of calvarial GCTB compared to skull-base lesions, the critical importance of achieving gross total resection, and the emerging role of molecular diagnosis (H3F3A G34W mutation) and adjuvant therapies including denosumab. Calvarial GCTB offers superior surgical accessibility and prognosis compared to skull-base counterparts, with appropriately aggressive resection typically achieving cure without need for radiotherapy, thereby avoiding the well-documented risk of radiation-induced malignant transformation.